The University of Texas MD Anderson Cancer Center and Exscientia plc today announced a strategic collaboration to align the drug discovery and development expertise of MD Anderson with the patient-centric artificial intelligence (AI) capabilities of Exscientia in order to advance novel small-molecule oncology therapies.
The research collaboration will utilize Exscientia’s precision medicine platform to identify novel anti-cancer...
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president...
ABSTRACTS: 374, 568, 590, 657, 659, 782
The University of Texas MD Anderson Cancer Center’s...